Table 2.
Univariate and Multivariate Predictors of Progression-Free Survival in the Whole Series (n = 106)
| Parameters | uHR | CI95% | P-value | aHR | CI95% | P-value | |
|---|---|---|---|---|---|---|---|
| Sex | Female | 1 (ref) | |||||
| Male | 1.37 | 0.55–3.41 | .487 | ||||
| Age, year | ≤40 | 1 (ref) | |||||
| >40 | 0.97 | 0.41–2.30 | .957 | ||||
| Preoperative KPS score | >70 | 1 (ref) | 1 (ref) | ||||
| ≤70 | 73.00 | 9.99–533.14 | <.001 | 19.07 | 2.06–176.45 | .009 | |
| Corpus callosum involvement | No | 1 (ref) | |||||
| Yes | 1.81 | 0.66–4.94 | .246 | ||||
| Glioma location | Frontal | 1 (ref) | |||||
| Temporal | 1.22 | 0.41–3.62 | .723 | ||||
| Insular | 1.17 | 0.39–3.49 | .774 | ||||
| Parietal | 0.60 | 0.14–2.58 | .496 | ||||
| Glioma side location | Left | 1 (ref) | |||||
| Right | 1.23 | 0.52–2.91 | .627 | ||||
| Tumor volume, cm3 | <45 | 1 (ref) | |||||
| ≥45 | 2.52 | 0.97–6.49 | .056 | ||||
| Hyperperfusion | No | 1 (ref) | |||||
| Yes | 1.92 | 0.78–4.78 | .367 | ||||
| Missing | N/A | ||||||
| Contrast enhancement | None | 1 (ref) | |||||
| Faint and patchy | 0.70 | 0.19–2.48 | .580 | ||||
| Nodular-like | 1.14 | 0.40–3.27 | .796 | ||||
| Ring-like | 1.75 | 0.22–13.49 | .592 | ||||
| Residual tumor, cm3 | Per unit | 1.02 | 1.00–1.04 | .017 | 1.03 | 1.00–1.05 | .028 |
| Histo-molecular diagnosis | Oligodendroglioma | 1 (ref) | 1 (ref) | ||||
| Astrocytoma | 3.15 | 1.15–8.62 | .025 | 3.59 | 1.13–11.39 | .029 | |
| Oncological treatment | Surgery only | 1 (ref) | |||||
| Surgery + RT/CHT | 1.02 | 0.34–3.06 | .969 |
aHR, adjusted hazard ratio; CI, confidence interval; CHT, chemotherapy; KPS, Karnofsky Performance Status; RT, radiotherapy; uHR, unadjusted hazard ratio.
Unadjusted hazard ratios by log-rank tests and adjusted hazard ratios by Cox proportional hazards model.
P-values in bold are significant.